Dipyridamole (tablet): Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Dipyridamole}} | {{Dipyridamole}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} {{SS}} | ||
'''''For patient information about Dipyridamole, click [[Dipyridamole (patient information)|here]]''''' | '''''For patient information about Dipyridamole, click [[Dipyridamole (patient information)|here]]''''' | ||
{{SB}} PERSANTINE<sup>®</sup> | |||
==Overview== | ==Overview== | ||
==Category== | ==Category== | ||
Cardiovascular Drugs: | |||
==US Brand Names== | ==US Brand Names== | ||
Revision as of 02:21, 7 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
For patient information about Dipyridamole, click here
Synonyms / Brand Names: PERSANTINE®
Overview
Category
Cardiovascular Drugs:
US Brand Names
FDA Package Insert
| Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages